Literature DB >> 25979349

Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial.

Rikako Hiramatsu1, Yoshifumi Ubara2, Naoki Sawa3, Junichi Hoshino3, Eiko Hasegawa3, Masahiro Kawada3, Aya Imafuku3, Keiichi Sumida3, Koki Mise3, Noriko Hayami3, Tatsuya Suwabe3, Kenmei Takaichi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25979349     DOI： 10.1053/j.ajkd.2015.03.012

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  15 in total

1.  Safety and efficacy of denosumab in osteoporotic hemodialysed patients.

Authors:  Francescaromana Festuccia; Maryam Tayefeh Jafari; Alessandra Moioli; Claudia Fofi; Simona Barberi; Stefano Amendola; Salvatore Sciacchitano; Giorgio Punzo; Paolo Menè
Journal:  J Nephrol       Date:  2016-07-09       Impact factor: 3.902

2.  Denosumab for treatment of immobilization-related hypercalcemia in a patient with end-stage renal disease.

Authors:  Atsuko Uehara; Masahiko Yazawa; Atsumi Kawata; Rina Hachisuka; Yugo Shibagaki
Journal:  CEN Case Rep       Date:  2017-02-27

Review 3.  Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease.

Authors:  Andrew L Lundquist; Sagar U Nigwekar
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-03       Impact factor: 2.894

Review 4.  Management of osteoporosis in patients with chronic kidney disease.

Authors:  M Abdalbary; M Sobh; S Elnagar; M A Elhadedy; N Elshabrawy; M Abdelsalam; K Asadipooya; A Sabry; A Halawa; A El-Husseini
Journal:  Osteoporos Int       Date:  2022-06-24       Impact factor: 5.071

Review 5.  Vitamin D in patients with chronic kidney disease: a position statement of the Working Group "Trace Elements and Mineral Metabolism" of the Italian Society of Nephrology.

Authors:  Luigi Francesco Morrone; Pergiorgio Bolasco; Corrado Camerini; Giuseppe Cianciolo; Adamasco Cupisti; Andrea Galassi; Sandro Mazzaferro; Domenico Russo; Luigi Russo; Mario Cozzolino
Journal:  J Nephrol       Date:  2016-04-09       Impact factor: 3.902

6.  Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?

Authors:  G Tsvetov; O Amitai; T Shochat; I Shimon; A Akirov; T Diker-Cohen
Journal:  Osteoporos Int       Date:  2019-12-14       Impact factor: 4.507

7.  The utility of FRAX® in predicting bone fractures in patients with chronic kidney disease on hemodialysis: a two-year prospective multicenter cohort study.

Authors:  J Przedlacki; J Buczyńska-Chyl; P Koźmiński; E Niemczyk; E Wojtaszek; E Gieglis; P Żebrowski; A Podgórzak; J Wściślak; M Wieliczko; J Matuszkiewicz-Rowińska
Journal:  Osteoporos Int       Date:  2018-02-06       Impact factor: 4.507

8.  Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.

Authors:  D Miyaoka; Y Imanishi; M Ohara; N Hayashi; Y Nagata; S Yamada; K Mori; M Emoto; M Inaba
Journal:  Osteoporos Int       Date:  2018-09-05       Impact factor: 4.507

9.  Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.

Authors:  C Thongprayoon; P Acharya; C Acharya; J Chenbhanich; T Bathini; B Boonpheng; K Sharma; K Wijarnpreecha; P Ungprasert; M L Gonzalez Suarez; W Cheungpasitporn
Journal:  Osteoporos Int       Date:  2018-04-30       Impact factor: 4.507

10.  Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study.

Authors:  Hiroya Takami; Kazunori Washio; Hiromichi Gotoh
Journal:  Int J Nephrol       Date:  2017-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.